Yang Li
李阳
Yang Li (李阳) is the co-founder and chairman of ReviR Therapeutics (溪砾科技), an AI-driven RNA-targeting drug discovery startup backed by 5Y Capital . He has represented the company across multiple funding milestones, from its early-stage development through its $30 million Series A in 2024 . At a 2021 5Y Capital forum on computational drug discovery, Li appeared alongside other portfolio-company founders as a practitioner in the AI+biotech space . In public statements he has framed ReviR's work as developing oral gene therapies that regulate genes at the RNA level, targeting previously "undruggable" conditions in neurological disorders and cancer .
AI-generated — may contain errors, please verify.
Coverage
5Y News | 5Y Capital Portfolio Company ReviR Therapeutics Raises $30 Million in Series A Funding
Continuing to advance "oral gene therapy" through AI+RNA.
五源资本·5Y News | AI+RNA Startup ReviR Therapeutics Closes Tens of Millions of Dollars in Pre-A Round
Using AI algorithms and gene technology to drive targeted RNA drug development.
五源资本·5Y Talk | How Can Computing and AI Break Through the Traditional Paradigm of Drug Discovery?
Entering the Game, Direction, and the Future.
五源资本·
